# Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

> **NCT00767000** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 813 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** MK-0941
- **DRUG:** Comparator: Placebo
- **BIOLOGICAL:** Lantus
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00767000
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2010-04
- **Final completion:** 2010-06
- **Target enrollment:** 813 (ACTUAL)
- **Last updated:** 2015-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00767000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00767000, "Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00767000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*